Barclays’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.6M | Buy |
+69,300
| New | +$10.6M | ﹤0.01% | 1425 |
|
|
2024
Q4 | – | Sell |
-117,600
| Closed | -$13.5M | – | 5409 |
|
|
2024
Q3 | $13.5M | Buy |
+117,600
| New | +$13.3M | ﹤0.01% | 1276 |
|
|
2023
Q1 | – | Sell |
-11,000
| Closed | -$998K | – | 5270 |
|
|
2022
Q4 | $998K | Buy |
+11,000
| New | +$926K | ﹤0.01% | 2802 |
|
|
2021
Q2 | – | Sell |
-120,000
| Closed | -$10.3M | – | 5021 |
|
|
2021
Q1 | $10.3M | Buy |
120,000
+100,400
| +512% | +$9.01M | 0.01% | 1073 |
|
|
2020
Q4 | $1.85M | Hold |
19,600
| – | – | ﹤0.01% | 2294 |
|
|
2020
Q3 | $1.7M | Sell |
19,600
-2,100
| -10% | -$182K | ﹤0.01% | 2246 |
|
|
2020
Q2 | $1.9M | Sell |
21,700
-64,700
| -75% | -$5.58M | ﹤0.01% | 2173 |
|
|
2020
Q1 | $7.12M | Sell |
86,400
-33,700
| -28% | -$3.01M | 0.01% | 1215 |
|
|
2019
Q4 | $11.4M | Sell |
120,100
-33,300
| -22% | -$2.99M | 0.01% | 1299 |
|
|
2019
Q3 | $13.3M | Buy |
153,400
+100,300
| +189% | +$9.01M | 0.01% | 1120 |
|
|
2019
Q2 | $4.85M | Buy |
53,100
+18,392
| +53% | +$1.56M | ﹤0.01% | 1889 |
|
|
2019
Q1 | $2.99M | Sell |
34,708
-60,710
| -64% | -$4.87M | ﹤0.01% | 2144 |
|
|
2018
Q4 | $7.34M | Buy |
95,418
+83,700
| +714% | +$6.52M | 0.01% | 1343 |
|
|
2018
Q3 | $905K | Sell |
11,718
-4,576
| -28% | -$338K | ﹤0.01% | 3721 |
|
|
2018
Q2 | $1.1M | Sell |
16,294
-20,980
| -56% | -$1.45M | ﹤0.01% | 3173 |
|
|
2018
Q1 | $2.7M | Sell |
37,274
-4,353
| -10% | -$331K | ﹤0.01% | 2176 |
|
|
2017
Q4 | $3.13M | Buy |
41,627
+28,681
| +222% | +$2.16M | ﹤0.01% | 2026 |
|
|
2017
Q3 | $996K | Sell |
12,946
-446
| -3% | -$33.7K | ﹤0.01% | 3005 |
|
|
2017
Q2 | $1M | Sell |
13,392
-35,042
| -72% | -$2.48M | ﹤0.01% | 2893 |
|
|
2017
Q1 | $3.22M | Sell |
48,434
-2,790
| -5% | -$186K | ﹤0.01% | 1657 |
|
|
2016
Q4 | $3.34M | Buy |
51,224
+34,819
| +212% | +$2.26M | ﹤0.01% | 1687 |
|
|
2016
Q3 | $1.16M | Sell |
16,405
-11,272
| -41% | -$821K | ﹤0.01% | 2492 |
|
|
2016
Q2 | $2.05M | Sell |
27,677
-1,339
| -5% | -$92.5K | ﹤0.01% | 1987 |
|
|
2016
Q1 | $1.87M | Buy |
29,016
+21,874
| +306% | +$1.49M | ﹤0.01% | 1978 |
|
|
2015
Q4 | $550K | Sell |
7,142
-3,572
| -33% | -$284K | ﹤0.01% | 3140 |
|
|
2015
Q3 | $874K | Buy |
10,714
+3,237
| +43% | +$288K | ﹤0.01% | 2860 |
|
|
2015
Q2 | $657K | Sell |
7,477
-2,009
| -21% | -$184K | ﹤0.01% | 3246 |
|
|
2015
Q1 | $833K | Sell |
9,486
-8,928
| -48% | -$792K | ﹤0.01% | 3140 |
|
|
2014
Q4 | $1.52M | Buy |
18,414
+4,799
| +35% | +$398K | ﹤0.01% | 2784 |
|
|
2014
Q3 | $1.15M | Sell |
13,615
-3,460
| -20% | -$280K | ﹤0.01% | 3201 |
|
|
2014
Q2 | $1.38M | Sell |
17,075
-53,345
| -76% | -$4.2M | ﹤0.01% | 3011 |
|
|
2014
Q1 | $5.36M | Buy |
70,420
+12,388
| +21% | +$903K | 0.01% | 1647 |
|
|
2013
Q4 | $4.16M | Buy |
58,032
+2,120
| +4% | +$147K | ﹤0.01% | 1982 |
|
|
2013
Q3 | $3.81M | Buy |
55,912
+16,182
| +41% | +$1.07M | ﹤0.01% | 1925 |
|
|
2013
Q2 | $2.52M | Buy |
+39,730
| New | +$2.58M | ﹤0.01% | 2288 |
|
Other funds holding NVS
Barclays's NVS Position: Q1 2026 in Review
Barclays increased its Novartis (NVS) stake by 1,727% in Q1 2026, buying an estimated $1.08M and bringing the position to 7,473 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #2675.
Barclays first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.8M in Q3 2020. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Barclays held 7,473 shares of Novartis worth $1.14M as of Q1 2026.
- Barclays bought 7,064 Novartis shares in Q1 2026, an estimated $1.08M.
- Novartis made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2675 holding.
- Barclays first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
- Barclays's Novartis position peaked at $10.8M in Q3 2020.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.